NCT03680521
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Carcinoma, Renal Cell
Explore clinical trials studying Carcinoma, Renal Cell. Study availability and eligibility vary by location and protocol.
1,363 public trials
252 recruiting studies
Carcinoma, Renal Cell trial results
NCT06055660
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
Not specified
NCT01517243
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States
- University of Vermont, Vermont Cancer Center Burlington, Vermont, United States
NCT02386826
- Conditions
- Adenocarcinoma, Astrocytoma, Carcinoma, +33 more
- Locations
-
- Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
- Yale School of Medicine New Haven, Connecticut, United States
- HCA Midwest - Kansas City Kansas City, Missouri, United States
- Oklahoma University Health Science Center Oklahoma City, Oklahoma, United States
NCT03207347
- Conditions
- Adenocarcinoma, Adenoma, Carcinoma, +29 more
- Locations
-
- University of Florida Gainesville, Florida, United States
- University of Miami Miami, Florida, United States
- Orlando Health UF Health Cancer Center Orlando, Florida, United States
NCT03200717
- Conditions
- Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +15 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
- Novartis Investigative Site Caba, Buenos Aires, Argentina
- Novartis Investigative Site Graz, Austria
- Novartis Investigative Site Salzburg, Austria
Completed
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
NCT00471432
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +49 more
- Locations
-
Not specified
NCT00075660
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- Cross Cancer Institute Edmonton, Alberta, Canada
- British Columbia Cancer Agency Vancouver, British Columbia, Canada
- CancerCare Manitoba Winnipeg, Manitoba, Canada
- Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada
Completed
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
NCT02855203
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
- Locations
-
- Princess Alexandra Hospital Woolloongabba, Queensland, Australia
- Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
NCT03602079
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bile Duct Cancer, +129 more
- Locations
-
- Florida Cancer Specialists & Research Institute Sarasota, Florida, United States
- Beth Israel Deaconess Medical Center Cancer Center Boston, Massachusetts, United States
- Karmanos Cancer Institute Detroit, Michigan, United States
- Clinical Research Alliance, Inc. Lake Success, New York, United States